<p>Modular Medical, Inc.（纳斯达克代码：MODD）（&#34;Modular Medical&#34;或&#34;公司&#34;）是一家胰岛素输送技术公司，拥有首个获得 FDA 批准的专为所有成年&#34;几乎使用泵&#34;的用户设计的贴片泵，具有用户友好和经济实惠的设计。今天，公司宣布收到纳斯达克证券市场有限责任公司（&#34;纳斯达克&#34;）上市资格部门的书面通知，批准公司请求延长 180 天以重新符合纳斯达克最低出价要求，根据纳斯达克上市规则 5810(c)(3)(A)（&#34;出价规则&#34;）。公司现在有直到 2026 年 6 月 29 日的时间来满足该要求。如果在 2026 年 6 月 29 日之前的任何时间，公司普通股的出价价格连续 10 个交易日收于每股 1.00 美元或以上，公司将重新符合出价规则。</p>
<p>如果公司在额外的 180 天延长期内未能重新符合出价规则，纳斯达克将向公司提供书面通知，告知其普通股将被退市。届时，公司可以根据适用的纳斯达克上市规则向听证小组上诉相关的退市决定。然而，如果公司向听证小组上诉纳斯达克的退市决定，不能保证该上诉会成功。</p>
<p>公司将继续监测其普通股的收盘出价，并评估可用的选项以重新符合出价规则。</p>
<p>纳斯达克的延长通知对公司普通股的上市或交易没有立即影响，该股票继续在纳斯达克资本市场以&#34;MODD&#34;的股票代码交易。</p>
<p><strong>安全港/前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的&#34;前瞻性声明&#34;，包括关于公司重新符合出价规则能力的声明，公司考虑实施可用选项以重新符合出价规则的计划，以及公司对任何未来退市决定上诉的意图。这些前瞻性声明面临风险和不确定性，可能导致实际结果与预期大相径庭，包括公司在任何合规期内或未来可能无法满足最低出价要求的风险，公司可能无法满足纳斯达克上市规则下持续上市要求的风险，纳斯达克可能不会在必要时给予公司免于退市的救济的风险，以及如果任何此类救济是必要的，公司可能最终无法满足适用的纳斯达克要求的风险，以及公司在向证券交易委员会提交的文件中不时详细列出的其他风险，并仅代表声明时的观点，不应被视为代表任何后续日期的观点。公司不承担更新任何前瞻性声明的义务。</p>
<p><strong>关于 Modular Medical, Inc.</strong></p>
<p>Modular Medical, Inc.（纳斯达克代码：MODD）是一家医疗设备公司，计划推出下一代胰岛素输送技术。利用其专利技术，公司旨在消除复杂性与有效性之间的权衡，从而使高质量的胰岛素输送既经济实惠又易于学习。其使命是改善糖尿病患者获得最高标准的血糖控制的机会，超越&#34;超级用户&#34;，为&#34;我们所有人提供糖尿病护理。&#34;</p>
<p>Modular Medical 由经验丰富的医疗设备专业人士和微流体工程师 Paul DiPerna 创立。在创立 Modular Medical 之前，DiPerna 先生于 2005 年创立了 Tandem Diabetes，并发明和设计了其 t:slim 胰岛素泵。更多信息请访问 https://modular-medical.com。</p>
<p>此处提及的所有商标均为其各自所有者的财产。</p>
<p><strong>联系方式：</strong></p>
<p>Jeb Besser</p>
<p>首席执行官</p>
<p>Modular Medical, Inc.</p>
<p>+1 (617) 399-1741</p>
<p>IR@modular-medical.com</p>
<p><strong>来源：</strong> Modular Medical, Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMjU0OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMjU0OQ"/></p>

MODD

<p>Modular Medical, Inc.（纳斯达克代码：MODD）已获得纳斯达克的 180 天延期，以符合最低出价要求。该公司必须在 2026 年 6 月 29 日之前连续 10 个交易日内实现每股 1.00 美元的出价，以重新获得合规资格。如果未能做到这一点，可能会导致退市，尽管公司可以对任何退市决定提出上诉。该延期不影响 MODD 股票在纳斯达克资本市场的当前交易状态</p>

<p>Modular Medical, Inc. (NASDAQ:MODD) (&#34;Modular Medical&#34; or the &#34;Company&#34;), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult &#34;almost-pumpers&#34; with its user-friendly and affordable design, today announced the Company received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (&#34;Nasdaq&#34;), granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5810(c)(3)(A) (the &#34;Bid Price Rule&#34;). The Company now has until June 29, 2026 to meet the requirement. If at any time prior to June 29, 2026, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule.</p>
<div class="lb-trans"><p>Modular Medical, Inc.（纳斯达克代码：MODD）（&#34;Modular Medical&#34;或&#34;公司&#34;）是一家胰岛素输送技术公司，拥有首个获得 FDA 批准的专为所有成年&#34;几乎使用泵&#34;的用户设计的贴片泵，具有用户友好和经济实惠的设计。今天，公司宣布收到纳斯达克证券市场有限责任公司（&#34;纳斯达克&#34;）上市资格部门的书面通知，批准公司请求延长 180 天以重新符合纳斯达克最低出价要求，根据纳斯达克上市规则 5810(c)(3)(A)（&#34;出价规则&#34;）。公司现在有直到 2026 年 6 月 29 日的时间来满足该要求。如果在 2026 年 6 月 29 日之前的任何时间，公司普通股的出价价格连续 10 个交易日收于每股 1.00 美元或以上，公司将重新符合出价规则。</p>
</div><p>If the Company does not regain compliance with the Bid Price Rule during the additional 180-day extension, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the relevant delisting determination to a Hearings Panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful.</p>
<div class="lb-trans"><p>如果公司在额外的 180 天延长期内未能重新符合出价规则，纳斯达克将向公司提供书面通知，告知其普通股将被退市。届时，公司可以根据适用的纳斯达克上市规则向听证小组上诉相关的退市决定。然而，如果公司向听证小组上诉纳斯达克的退市决定，不能保证该上诉会成功。</p>
</div><p>The Company will continue to monitor the closing bid price of its common stock and evaluate its available options to regain compliance with the Bid Price Rule.</p>
<div class="lb-trans"><p>公司将继续监测其普通股的收盘出价，并评估可用的选项以重新符合出价规则。</p>
</div><p>Nasdaq's extension notice has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the ticker symbol, &#34;MODD.&#34;</p>
<div class="lb-trans"><p>纳斯达克的延长通知对公司普通股的上市或交易没有立即影响，该股票继续在纳斯达克资本市场以&#34;MODD&#34;的股票代码交易。</p>
</div><p><strong>Safe Harbor/Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>安全港/前瞻性声明</strong></p>
</div><p>This press release contains &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's ability to regain compliance with the Bid Price Rule, the Company's plans to consider implementing available options to regain compliance with the Bid Price Rule and the Company's intention to appeal any future delisting determination. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risk that the Company may not meet the minimum bid price requirement during any compliance period or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, and represent views only as of the date they are made and should not be relied upon as representing views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的&#34;前瞻性声明&#34;，包括关于公司重新符合出价规则能力的声明，公司考虑实施可用选项以重新符合出价规则的计划，以及公司对任何未来退市决定上诉的意图。这些前瞻性声明面临风险和不确定性，可能导致实际结果与预期大相径庭，包括公司在任何合规期内或未来可能无法满足最低出价要求的风险，公司可能无法满足纳斯达克上市规则下持续上市要求的风险，纳斯达克可能不会在必要时给予公司免于退市的救济的风险，以及如果任何此类救济是必要的，公司可能最终无法满足适用的纳斯达克要求的风险，以及公司在向证券交易委员会提交的文件中不时详细列出的其他风险，并仅代表声明时的观点，不应被视为代表任何后续日期的观点。公司不承担更新任何前瞻性声明的义务。</p>
</div><p><strong>About Modular Medical, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Modular Medical, Inc.</strong></p>
</div><p>Modular Medical, Inc. (NASDAQ:MODD) is a medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond &#34;superusers&#34; and providing &#34;diabetes care for the rest of us.&#34;</p>
<div class="lb-trans"><p>Modular Medical, Inc.（纳斯达克代码：MODD）是一家医疗设备公司，计划推出下一代胰岛素输送技术。利用其专利技术，公司旨在消除复杂性与有效性之间的权衡，从而使高质量的胰岛素输送既经济实惠又易于学习。其使命是改善糖尿病患者获得最高标准的血糖控制的机会，超越&#34;超级用户&#34;，为&#34;我们所有人提供糖尿病护理。&#34;</p>
</div><p>Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.</p>
<div class="lb-trans"><p>Modular Medical 由经验丰富的医疗设备专业人士和微流体工程师 Paul DiPerna 创立。在创立 Modular Medical 之前，DiPerna 先生于 2005 年创立了 Tandem Diabetes，并发明和设计了其 t:slim 胰岛素泵。更多信息请访问 https://modular-medical.com。</p>
</div><p>All trademarks mentioned herein are the property of their respective owners.</p>
<div class="lb-trans"><p>此处提及的所有商标均为其各自所有者的财产。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Jeb Besser</p>
<div class="lb-trans"><p>Jeb Besser</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>Modular Medical, Inc.</p>
<div class="lb-trans"><p>Modular Medical, Inc.</p>
</div><p>+1 (617) 399-1741</p>
<div class="lb-trans"><p>+1 (617) 399-1741</p>
</div><p>IR@modular-medical.com</p>
<div class="lb-trans"><p>IR@modular-medical.com</p>
</div><p><strong>SOURCE:</strong> Modular Medical, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Modular Medical, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMjU0OQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1122549"/></p>

Modular Medical 获得 180 天的延期，以重新符合纳斯达克最低出价规则 | MODD 股票新闻